Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome second-line therapy in small cell lung cancer
CTR20200282Phase 2Terminated
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Apr 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone in small cell lung cancer (SCLC), sponsored by CSPC Pharmaceutical Group. Started Apr 2020; status: terminated.
02
Drugs
mitoxantrone
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20200282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200282.